Download view PDF 667 KB

The table below is an on-line supplement to McDonald GB, Frieze DA. A problem-oriented approach to
liver disease in oncology patients. Gut 2008; 57: 987 – 1003. This table provides references to the
studies summarized in Table 2. Common multidrug chemotherapy regimens and their frequency of liver
injury: evidence from published clinical trials. This table is organized alphabetically by the cancer being
treated. The drugs and regimens listed are those in common use for the malignancies listed.
Table 2 Common multidrug chemotherapy regimens and their frequency of liver injury: evidence
from published clinical trials
Regimen
Number
Number Frequency Frequency
Any
References
of
of studies of liver
of more
cases of
patients
evaluated abnormaliti severe liver
fatal
evaluated
es
injury
liver
injury?
Acute Lymphocytic Leukemia
Hyper-CVAD
556
6
5%
<1%
No
1-6
L-asparaginase
3
3%
<1%
Yes
7-9
3
50 – 60%
4%
No
10-11, 12
8
13-26%
12-24%
Yes
9, 13-20
2039
3
None
None
No
21-22, 23
480
1
<1%
None
No
24
2247
8
<1%
<1%
No
24-31
Chronic Lymphocytic Leukemia
Alemtuzumab
1343
13
<1%
<1%
Yes
32-44
Fludarabine-
<1%
<1%
No
45-51
661
Acute Myelogenous Leukemia
Cytarabine and
268
idarubicin (7+3)
Gemtuzumab
533
Breast Cancer
Doxorubicin and
cyclophosphamide
followed by
paclitaxel
5-fluorouracil,
doxorubicin and
cyclophosphamide
(FAC)
Cyclophosphamide,
methotrexate and 5fluorouracil (CMF)
1008
7
cyclophosphamide
Chronic Myelogenous Leukemia
Imatinib
1583
1 study
and 5 case
reports
1-3%
1-3%
Yes
52-57
11
None
None
No
58-68
4
None
None
No
69-72
6
None
None
No
73-78
9
2.5%
None
No
75, 78-85
6
None
None
No
86-91
2
None
None
No
86, 87
1752
12
None
None
No
92-103
358
4
<1%
<1%
No
92,104-106
Colorectal Cancer (CRC)
5-fluorouracil and
3293
leucovorin
(5-FU/LV)
Irinotecan, bolus 5452
fluorouracil and
leucovorin (IFL)
Irinotecan,
771
continuous infusion
5-fluorouracil and
leucovorin
(FOLFIRI)
Oxaliplatin,
1009
continuous infusion
5-fluorouracil and
leucovorin
(FOLFOX)
Head and Neck Cancer
Cisplatin-5786
fluorouracil
Cisplatin, 5424
fluorouracil and
docetaxel
Hodgkin’s Disease
Doxorubicin,
bleomycin,
vincristine,
dacarbazine
(ABVD)
Nitrogen mustard,
doxorubicin,
vinblastine,
vincristine,
bleomycin,
etoposide and
prednisone
(Stanford V)
Non Hodgkin’s Lymphoma (NHL)
Cyclophosphamide,
1173
12
doxorubicin,
vincristine and
prednisone (CHOP)
Rituximab
558
2
(Rituxan)
Ifosfamide,
380
6
etoposide and
carboplatin (ICE)
Etoposide,
417
8
methylprednisolone
, cisplatin and
cytarabine
(ESHAP)
Ibritumomab
172
5
Tiuxetan (Zevalin)
Tositumomab and
122
2
131
Iodine
Tositumomab
(Bexxar)
Non-Small Cell Lung Cancer
Cisplatin2789
gemcitabine
Carboplatin689
paclitaxel
Cisplatin719
vinorelbine
Ovarian Cancer
Carboplatinpaclitaxel
Cisplatin-paclitaxel
Cisplatin-paclitaxel
(intraperitoneal)
<1%
<1%
No
107-119
6%
1%
No
118-122
5%
<1%
No
123-128
<1%
None
No
129-136
1%
None
No
137-141
None
None
No
142, 143
28
2-5%
<1%
No
144-171
4
1%
<1%
No
168,154, 159, 172
5
1%
<1%
No
168,163,154, 155,
173
2486
8
<1%
<1%
No
174-181
1001
210
3
1
<1%
3%
<1%
3%
No
No
177, 181, 182
Pancreatic Cancer
Gemcitabine
Gemcitabine and
erlotinib
1352
308
8
2
6-17%
10-12%
3-4%
10-11%
No
No
183-190
Prostate Cancer
Docetaxelprednisone
662
1
None
None
No
192
182
184, 191
Mitoxantroneprednisone
Small Cell Lung
Cisplatin-etoposide
Cisplatin-irinotecan
799
4
1%
1%
No
192-195
1873
421
11
5
1-3%
4-16%
<1%
1-2%
No
No
156,196-205
156, 204, 206-208
1.
Koller CA, Kantarjian HM, Thomas D, et al. The hyper-CVAD regimen improves
outcome in relapsed acute lymphoblastic leukemia. Leukemia 1997;11(12):2039-44.
2.
Kantarjian H, Thomas D, O'Brien S, et al. Long-term follow-up results of
hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone
(Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer
2004;101(12):2788-801.
3.
Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyperCVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol
2000;18(3):547-61.
4.
Thomas DA, Cortes J, O'Brien S, et al. Hyper-CVAD program in Burkitt's-type
adult acute lymphoblastic leukemia. J Clin Oncol 1999;17(8):2461-70.
5.
Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD
plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute
lymphoblastic leukemia. Cancer 2006;106(7):1569-80.
6.
Thomas DA, O'Brien S, Cortes J, et al. Outcome with the hyper-CVAD regimens
in lymphoblastic lymphoma. Blood 2004;104(6):1624-30.
7.
Rizzari C, Valsecchi MG, Arico M, et al. Effect of protracted high-dose Lasparaginase given as a second exposure in a Berlin-Frankfurt-Munster-based treatment:
results of the randomized 9102 intermediate-risk childhood acute lymphoblastic leukemia
study--a report from the Associazione Italiana Ematologia Oncologia Pediatrica. J Clin
Oncol 2001;19(5):1297-303.
8.
Chim CS, Kwong YL, Chu YC, Chan CH, Chan YT, Liang R. Improved
treatment outcome in adult acute lymphoblastic leukemia using the intensive German
protocol, a preliminary report. Hematol Oncol 1997;15(1):19-26.
9.
Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with
acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood
2001;97(5):1211-8.
10.
Vogler WR, Velez-Garcia E, Weiner RS, et al. A phase III trial comparing
idarubicin and daunorubicin in combination with cytarabine in acute myelogenous
leukemia: a Southeastern Cancer Study Group Study. J Clin Oncol 1992;10(7):1103-11.
11.
Berman E, Heller G, Santorsa J, et al. Results of a randomized trial comparing
idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult
patients with newly diagnosed acute myelogenous leukemia. Blood 1991;77(8):1666-74.
12.
Wiernik PH, Banks PL, Case DC, Jr., et al. Cytarabine plus idarubicin or
daunorubicin as induction and consolidation therapy for previously untreated adult
patients with acute myeloid leukemia. Blood 1992;79(2):313-9.
13.
Larson RA, Sievers EL, Stadtmauer EA, et al. Final report of the efficacy and
safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute
myeloid leukemia in first recurrence. Cancer 2005;104(7):1442-52.
14.
Robillard N, Wuilleme S, Lode L, Magrangeas F, Minvielle S, Avet-Loiseau H.
CD33 is expressed on plasma cells of a significant number of myeloma patients, and may
represent a therapeutic target. Leukemia 2005;19(11):2021-2.
15.
Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab
ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin
Oncol 2001;19(13):3244-54.
16.
Brethon B, Auvrignon A, Galambrun C, et al. Efficacy and tolerability of
gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg) in
children with relapsed/refractory myeloid leukemia. BMC Cancer 2006;6:172.
17.
Roman E, Cooney E, Harrison L, et al. Preliminary results of the safety of
immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic
stem cell transplant in children with CD33+ acute myeloid leukemia. Clin Cancer Res
2005;11(19 Pt 2):7164s-70s.
18.
Arceci RJ, Sande J, Lange B, et al. Safety and efficacy of gemtuzumab
ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia. Blood
2005;106(4):1183-8.
19.
Lo-Coco F, Cimino G, Breccia M, et al. Gemtuzumab ozogamicin (Mylotarg) as a
single agent for molecularly relapsed acute promyelocytic leukemia. Blood
2004;104(7):1995-9.
20.
Nabhan C, Rundhaugen LM, Riley MB, et al. Phase II pilot trial of gemtuzumab
ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older.
Leuk Res 2005;29(1):53-7.
21.
Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus
conventionally scheduled and sequential versus concurrent combination chemotherapy as
postoperative adjuvant treatment of node-positive primary breast cancer: first report of
Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol
2003;21(8):1431-9.
22.
Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after doxorubicin plus
cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results
from NSABP B-28. J Clin Oncol 2005;23(16):3686-96.
23.
Hurria A, Brogan K, Panageas KS, et al. Patterns of toxicity in older patients with
breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat 2005;92(2):1516.
24.
Martin M, Villar A, Sole-Calvo A, et al. Doxorubicin in combination with
fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in
combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as
adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group. Ann
Oncol 2003;14(6):833-42.
25.
Ejlertsen B, Mouridsen HT, Jensen MB, et al. Improved outcome from
substituting methotrexate with epirubicin: results from a randomised comparison of CMF
versus CEF in patients with primary breast cancer. Eur J Cancer 2007;43(5):877-84.
26.
von Minckwitz G, Graf E, Geberth M, et al. CMF versus goserelin as adjuvant
therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal
patients: a randomised trial (GABG trial IV-A-93). Eur J Cancer 2006;42(12):1780-8.
27.
Falo C, Moreno A, Benito E, et al. Primary chemotherapy with
cyclophosphamide, methotrexate, and 5-fluorouracil in operable breast carcinoma.
Cancer 2005;103(4):657-63.
28.
Ron IG, Wigler N, Borovik R, et al. CMF (cyclophosphamide, methotrexate, 5fluorouracil) versus cnf (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant
chemotherapy for stage II lymph-node positive breast cancer: a phase III randomized
multicenter study. Am J Clin Oncol 2001;24(4):323-7.
29.
Rizzi V, Cioschi B, Cartei G, Bertolissi A, Tabaro G, Marsilio P. Liver function
tests and lidocaine metabolism (MEGX test) during i.v. CMF therapy in breast cancer.
Anticancer Drugs 1996;7(8):846-50.
30.
Fisher B, Dignam J, Mamounas EP, et al. Sequential methotrexate and
fluorouracil for the treatment of node-negative breast cancer patients with estrogen
receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and
Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing
methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and
fluorouracil. J Clin Oncol 1996;14(7):1982-92.
31.
Harper-Wynne C, English J, Meyer L, et al. Randomized trial to compare the
efficacy and toxicity of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with
methotrexate mitoxantrone (MM) in advanced carcinoma of the breast. Br J Cancer
1999;81(2):316-22.
32.
Karlsson C, Hansson L, Celsing F, Lundin J. Treatment of severe refractory
autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with
alemtuzumab (humanized CD52 monoclonal antibody). Leukemia 2007;21(3):511-4.
33.
Fiegl M, Falkner A, Hopfinger G, et al. Routine clinical use of alemtuzumab in
patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide
retrospective study in Austria. Cancer 2006;107(10):2408-16.
34.
Montillo M, Tedeschi A, Miqueleiz S, et al. Alemtuzumab as consolidation after a
response to fludarabine is effective in purging residual disease in patients with chronic
lymphocytic leukemia. J Clin Oncol 2006;24(15):2337-42.
35.
Nabhan C, Patton D, Gordon LI, et al. A pilot trial of rituximab and alemtuzumab
combination therapy in patients with relapsed and/or refractory chronic lymphocytic
leukemia (CLL). Leuk Lymphoma 2004;45(11):2269-73.
36.
Faderl S, Thomas DA, O'Brien S, et al. Experience with alemtuzumab plus
rituximab in patients with relapsed and refractory lymphoid malignancies. Blood
2003;101(9):3413-5.
37.
Rai KR, Freter CE, Mercier RJ, et al. Alemtuzumab in previously treated chronic
lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol
2002;20(18):3891-7.
38.
Lundin J, Kimby E, Bjorkholm M, et al. Phase II trial of subcutaneous anti-CD52
monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with
B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002;100(3):768-73.
39.
Montillo M, Cafro AM, Tedeschi A, et al. Safety and efficacy of subcutaneous
Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia
responding to fludarabine. Haematologica 2002;87(7):695-700; discussion
40.
Osterborg A, Dyer MJ, Bunjes D, et al. Phase II multicenter study of human
CD52 antibody in previously treated chronic lymphocytic leukemia. European Study
Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol
1997;15(4):1567-74.
41.
Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath1H) in patients who have failed fludarabine: results of a large international study. Blood
2002;99(10):3554-61.
42.
In: Campath Package Insert. Cambridge, MA: Genzyme Corporation; 2007.
43.
McCune SL, Gockerman JP, Moore JO, et al. Alemtuzumab in relapsed or
refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Leuk Lymphoma
2002;43(5):1007-11.
44.
Lin TS, Flinn IW, Lucas MS, et al. Filgrastim and alemtuzumab (Campath-1H)
for refractory chronic lymphocytic leukemia. Leukemia 2005;19(7):1207-10.
45.
Flinn IW, Neuberg DS, Grever MR, et al. Phase III trial of fludarabine plus
cyclophosphamide compared with fludarabine for patients with previously untreated
chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 2007;25(7):7938.
46.
Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus
cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4
Trial): a randomised controlled trial. Lancet 2007;370(9583):230-9.
47.
O'Brien S, Moore JO, Boyd TE, et al. Randomized phase III trial of fludarabine
plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients
with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 2007;25(9):111420.
48.
Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide
versus fludarabine alone in first-line therapy of younger patients with chronic
lymphocytic leukemia. Blood 2006;107(3):885-91.
49.
Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy
regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic
lymphocytic leukemia. J Clin Oncol 2005;23(18):4079-88.
50.
O'Brien SM, Kantarjian HM, Cortes J, et al. Results of the fludarabine and
cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol
2001;19(5):1414-20.
51.
Hallek M, Schmitt B, Wilhelm M, et al. Fludarabine plus cyclophosphamide is an
efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase
II study of the German CLL Study Group. Br J Haematol 2001;114(2):342-8.
52.
Data on File. In. East Hanover, NJ: Novartis Oncology; 2007.
53.
Ayoub WS, Geller SA, Tran T, Martin P, Vierling JM, Poordad FF. Imatinib
(Gleevec)-induced hepatotoxicity. J Clin Gastroenterol 2005;39(1):75-7.
54.
James C, Trouette H, Marit G, Cony-Makhoul P, Mahon FX. Histological features
of acute hepatitis after imatinib mesylate treatment. Leukemia 2003;17(5):978-9.
55.
Lin NU, Sarantopoulos S, Stone JR, et al. Fatal hepatic necrosis following
imatinib mesylate therapy. Blood 2003;102(9):3455-6.
56.
Ohyashiki K, Kuriyama Y, Nakajima A, et al. Imatinib mesylate-induced hepatotoxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral
hepatitis. Leukemia 2002;16(10):2160-1.
57.
Ikeda K, Shiga Y, Takahashi A, et al. Fatal hepatitis B virus reactivation in a
chronic myeloid leukemia patient during imatinib mesylate treatment. Leuk Lymphoma
2006;47(1):155-7.
58.
O'Connell MJ. A phase III trial of 5-fluorouracil and leucovorin in the treatment
of advanced colorectal cancer. A Mayo Clinic/North Central Cancer Treatment Group
study. Cancer 1989;63(6 Suppl):1026-30.
59.
Jager E, Heike M, Bernhard H, et al. Weekly high-dose leucovorin versus lowdose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a
randomized multicenter trial.Study Group for Palliative Treatment of Metastatic
Colorectal Cancer Study Protocol 1. J Clin Oncol 1996;14(8):2274-9.
60.
Kohne CH, Wils J, Lorenz M, et al. Randomized phase III study of high-dose
fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus
fluorouracil plus leucovorin in advanced colorectal cancer: European organization of
Research and Treatment of Cancer Gastrointestinal Group Study 40952. J Clin Oncol
2003;21(20):3721-8.
61.
de Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly
low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and
fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French
intergroup study. J Clin Oncol 1997;15(2):808-15.
62.
Petrelli N, Douglass HO, Jr., Herrera L, et al. The modulation of fluorouracil with
leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial.
Gastrointestinal Tumor Study Group. J Clin Oncol 1989;7(10):1419-26.
63.
Buroker TR, O'Connell MJ, Wieand HS, et al. Randomized comparison of two
schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J
Clin Oncol 1994;12(1):14-20.
64.
Chau I, Norman AR, Cunningham D, et al. A randomised comparison between 6
months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion
fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol 2005;16(4):549-57.
65.
Aranda E, Diaz-Rubio E, Cervantes A, et al. Randomized trial comparing
monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour
continuous-infusion fluorouracil for advanced colorectal cancer: a Spanish Cooperative
Group for Gastrointestinal Tumor Therapy (TTD) study. Ann Oncol 1998;9(7):727-31.
66.
Erlichman C, Fine S, Wong A, Elhakim T. A randomized trial of fluorouracil and
folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 1988;6(3):46975.
67.
Wolmark N, Rockette H, Fisher B, et al. The benefit of leucovorin-modulated
fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from
National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol
1993;11(10):1879-87.
68.
O'Connell MJ, Mailliard JA, Kahn MJ, et al. Controlled trial of fluorouracil and
low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon
cancer. J Clin Oncol 1997;15(1):246-50.
69.
Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for
metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343(13):90514.
70.
Barcelo R, Lopez Vivanco G, Rivera F, et al. Irinotecan (CPT-11) combined with
bolus 5-fluorouracil/leucovorin (Saltz regimen) as first-line chemotherapy of patients
with advanced colorectal cancer. Anticancer Drugs 2006;17(1):89-94.
71.
Moehler M, Hoffmann T, Zanke C, et al. Safety and efficacy of outpatient
treatment with CPT-11 plus bolus folinic acid/5-fluorouracil as first-line chemotherapy
for metastatic colorectal cancer. Anticancer Drugs 2003;14(1):79-85.
72.
Bouzid K, Khalfallah S, Tujakowski J, et al. A randomized phase II trial of
irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic
acid regimens as first-line therapy for advanced colorectal cancer. Ann Oncol
2003;14(7):1106-14.
73.
Souglakos J, Pallis A, Kakolyris S, et al. Combination of irinotecan (CPT-11) plus
5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly
patients with metastatic colorectal cancer: a phase II trial. Oncology 2005;69(5):384-90.
74.
Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with
fluorouracil compared with fluorouracil alone as first-line treatment for metastatic
colorectal cancer: a multicentre randomised trial. Lancet 2000;355(9209):1041-7.
75.
Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the
reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin
Oncol 2004;22(2):229-37.
76.
Souglakos J, Androulakis N, Syrigos K, et al. FOLFOXIRI (folinic acid, 5fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and
irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre
randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J
Cancer 2006;94(6):798-805.
77.
Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil,
leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional
fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic
colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007;25(13):1670-6.
78.
Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI
versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of
the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005;23(22):4866-75.
79.
Kemeny N, Garay CA, Gurtler J, et al. Randomized multicenter phase II trial of
bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus
oxaliplatin as third-line treatment of patients with advanced colorectal cancer. J Clin
Oncol 2004;22(23):4753-61.
80.
Emmanouilides C, Sfakiotaki G, Androulakis N, et al. Front-line bevacizumab in
combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with
metastatic colorectal cancer: a multicenter phase II study. BMC Cancer 2007;7:91.
81.
Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of
FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced
colorectal cancer--a GERCOR study. J Clin Oncol 2006;24(3):394-400.
82.
Alberts SR, Horvath WL, Sternfeld WC, et al. Oxaliplatin, fluorouracil, and
leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a
North Central Cancer Treatment Group phase II study. J Clin Oncol 2005;23(36):9243-9.
83.
Maindrault-Goebel F, de Gramont A, Louvet C, et al. Evaluation of oxaliplatin
dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion
regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology
Multidisciplinary Research Group (GERCOR). Ann Oncol 2000;11(11):1477-83.
84.
Shimizu T, Satoh T, Tamura K, et al. Oxaliplatin/fluorouracil/leucovorin
(FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal
cancer: post-approval Japanese population experience. Int J Clin Oncol 2007;12(3):21823.
85.
Park SH, Sung JY, Han SH, et al. Oxaliplatin, folinic acid and 5-fluorouracil
(FOLFOX-4) combination chemotherapy as second-line treatment in advanced colorectal
cancer patients with irinotecan failure: a Korean single-center experience. Jpn J Clin
Oncol 2005;35(9):531-5.
86.
Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or
with docetaxel in head and neck cancer. N Engl J Med 2007;357(17):1705-15.
87.
Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and
docetaxel in unresectable head and neck cancer. N Engl J Med 2007;357(17):1695-704.
88.
Domenge C, Hill C, Lefebvre JL, et al. Randomized trial of neoadjuvant
chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la
Tete et du Cou (GETTEC). Br J Cancer 2000;83(12):1594-8.
89.
De Andres L, Brunet J, Lopez-Pousa A, et al. Randomized trial of neoadjuvant
cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IVM0 head and neck cancer. J Clin Oncol 1995;13(6):1493-500.
90.
Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin
plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced
squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J
Clin Oncol 1992;10(8):1245-51.
91.
Jacobs C, Lyman G, Velez-Garcia E, et al. A phase III randomized study
comparing cisplatin and fluorouracil as single agents and in combination for advanced
squamous cell carcinoma of the head and neck. J Clin Oncol 1992;10(2):257-63.
92.
Gobbi PG, Levis A, Chisesi T, et al. ABVD versus modified stanford V versus
MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advancedstage Hodgkin's lymphoma: final results of a multicenter randomized trial by the
Intergruppo Italiano Linfomi. J Clin Oncol 2005;23(36):9198-207.
93.
Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of
ABVD chemotherapy with a strategy that includes radiation therapy in patients with
limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials
Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23(21):4634-42.
94.
Rueda Dominguez A, Marquez A, Guma J, et al. Treatment of stage I and II
Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective
study. Ann Oncol 2004;15(12):1798-804.
95.
Straus DJ, Portlock CS, Qin J, et al. Results of a prospective randomized clinical
trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by
radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin
disease. Blood 2004;104(12):3483-9.
96.
Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD
plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease:
long-term results. J Clin Oncol 2004;22(14):2835-41.
97.
Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD
and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an
intergroup trial. J Clin Oncol 2003;21(4):607-14.
98.
Brusamolino E, Lunghi F, Orlandi E, et al. Treatment of early-stage Hodgkin's
disease with four cycles of ABVD followed by adjuvant radio-therapy: analysis of
efficacy and long-term toxicity. Haematologica 2000;85(10):1032-9.
99.
Zinzani PL, Magagnoli M, Frezza G, et al. ABVD and radiation therapy as firstline treatment in advanced Hodgkin's disease. Leuk Lymphoma 1999;32(5-6):553-9.
100. Andrieu JM, Jais JP, Colonna P, et al. Ten-year results of a strategy combining
three cycles of ABVD and high-dose extended irradiation for treating Hodgkin's disease
at advanced stages. Ann Oncol 1998;9(2):195-203.
101. Hirsch A, Vander Els N, Straus DJ, et al. Effect of ABVD chemotherapy with and
without mantle or mediastinal irradiation on pulmonary function and symptoms in earlystage Hodgkin's disease. J Clin Oncol 1996;14(4):1297-305.
102. Carde P, Hagenbeek A, Hayat M, et al. Clinical staging versus laparotomy and
combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6
twin randomized trials from the European Organization for Research and Treatment of
Cancer Lymphoma Cooperative Group. J Clin Oncol 1993;11(11):2258-72.
103. Santoro A, Bonadonna G, Valagussa P, et al. Long-term results of combined
chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus
radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 1987;5(1):27-37.
104. Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA.
Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease:
mature results of a prospective clinical trial. J Clin Oncol 2002;20(3):630-7.
105. Horning SJ, Williams J, Bartlett NL, et al. Assessment of the stanford V regimen
and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern
Cooperative Oncology Group pilot study E1492. J Clin Oncol 2000;18(5):972-80.
106. Bartlett NL, Rosenberg SA, Hoppe RT, Hancock SL, Horning SJ. Brief
chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage
Hodgkin's disease: a preliminary report. J Clin Oncol 1995;13(5):1080-8.
107. Mori M, Niitsu N, Takagi T, et al. Reduced-dose chop therapy for elderly patients
with non-Hodgkin's lymphoma. Leuk Lymphoma 2001;41(3-4):359-66.
108. Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP
chemotherapy with or without etoposide for the treatment of elderly patients with
aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood
2004;104(3):634-41.
109. Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP
chemotherapy with or without etoposide for the treatment of young patients with goodprognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the
DSHNHL. Blood 2004;104(3):626-33.
110. Cooper IA, Wolf MM, Robertson TI, et al. Randomized comparison of MACOPB with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The
Australian and New Zealand Lymphoma Group. J Clin Oncol 1994;12(4):769-78.
111. Meyer RM, Browman GP, Samosh ML, et al. Randomized phase II comparison of
standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma. J
Clin Oncol 1995;13(9):2386-93.
112. Tirelli U, Errante D, Van Glabbeke M, et al. CHOP is the standard regimen in
patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's
lymphoma: results of a randomized study of the European Organization for Research and
Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol 1998;16(1):2734.
113. Gomez H, Mas L, Casanova L, et al. Elderly patients with aggressive nonHodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage
colony-stimulating factor: identification of two age subgroups with differing hematologic
toxicity. J Clin Oncol 1998;16(7):2352-8.
114. Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ. Prolonged
clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's
lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin
Oncol 2004;22(23):4711-6.
115. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen
(CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's
lymphoma. N Engl J Med 1993;328(14):1002-6.
116. Meyer RM, Gyger M, Langley R, Lesperance B, Caplan SN. A phase I trial of
standard and cyclophosphamide dose-escalated CHOP with granulocyte colony
stimulating factor in elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma
1998;30(5-6):591-600.
117. Saab S, Dong MH, Joseph TA, Tong MJ. Hepatitis B prophylaxis in patients
undergoing chemotherapy for lymphoma: A decision analysis model. Hepatology 2007.
118. Law JK, Ho JK, Hoskins PJ, Erb SR, Steinbrecher UP, Yoshida EM. Fatal
reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface
antigen-negative, hepatitis B core antibody-positive patient: potential implications for
future prophylaxis recommendations. Leuk Lymphoma 2005;46(7):1085-9.
119. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab
compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N
Engl J Med 2002;346(4):235-42.
120. Rituxan Package Insert. In. San Francisco, CA: Genentech Inc.; 2007.
121. Tsutsumi Y, Kawamura T, Saitoh S, et al. Hepatitis B virus reactivation in a case
of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of
prophylaxis for hepatitis B virus reactivation in rituximab therapy. Leuk Lymphoma
2004;45(3):627-9.
122. Aksoy S, Abali H, Kilickap S, Erman M, Kars A. Accelerated hepatitis C virus
replication with rituximab treatment in a non-Hodgkin's lymphoma patient. Clin Lab
Haematol 2006;28(3):211-4.
123. Moskowitz CH, Bertino JR, Glassman JR, et al. Ifosfamide, carboplatin, and
etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell
mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J
Clin Oncol 1999;17(12):3776-85.
124. Hertzberg MS, Crombie C, Benson W, Taper J, Gottlieb D, Bradstock KF.
Outpatient-based ifosfamide, carboplatin and etoposide (ICE) chemotherapy in
transplant-eligible patients with non-Hodgkin's lymphoma and Hodgkin's disease. Ann
Oncol 2003;14 Suppl 1:i11-6.
125. Vose J, Sneller V. Outpatient regimen rituximab plus ifosfamide, carboplatin and
etoposide (R-ICE) for relapsed non-Hodgkin's lymphoma. Ann Oncol 2003;14 Suppl
1:i17-20.
126. Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line
therapy before autologous stem cell transplantation for relapsed or primary refractory
diffuse large B-cell lymphoma. Blood 2004;103(10):3684-8.
127. Hertzberg MS, Crombie C, Benson W, Taper J, Gottlieb D, Bradstock KF.
Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in
relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma. Ann Oncol 2006;17
Suppl 4:iv25-30.
128. Jerkeman M, Leppa S, Kvaloy S, Holte H. ICE (ifosfamide, carboplatin,
etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive
lymphoma--the Nordic Lymphoma Group experience. Eur J Haematol 2004;73(3):17982.
129. Wang WS, Chiou TJ, Liu JH, et al. ESHAP as salvage therapy for refractory nonHodgkin's lymphoma: Taiwan experience. Jpn J Clin Oncol 1999;29(1):33-7.
130. Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP--an effective
chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J
Clin Oncol 1994;12(6):1169-76.
131. Ezzat AA, Khalifa F, Berry J, Khan B, Raja MA, Abdel-Warith A. E-SHAP: an
effective treatment in selected patients with relapsed non-Hodgkin's lymphoma. Ann
Oncol 1994;5(5):453-6.
132. Soussain C, Souleau B, Gabarre J, et al. Intensive chemotherapy with
hematopoietic cell transplantation after ESHAP therapy for relapsed or refractory nonHodgkin's lymphoma. Results of a single-centre study of 65 patients. Leuk Lymphoma
1999;33(5-6):543-50.
133. Petit J, Boque C, Cancelas JA, et al. Feasibility of ESHAP + G-CSF as peripheral
blood hematopoietic progenitor cell mobilisation regimen in resistant and relapsed
lymphoma: a single-center study of 22 patients. Leuk Lymphoma 1999;34(1-2):119-27.
134. Choi CW, Paek CW, Seo JH, et al. ESHAP salvage therapy for relapsed or
refractory non-Hodgkin's lymphoma. J Korean Med Sci 2002;17(5):621-4.
135. Watts MJ, Ings SJ, Leverett D, et al. ESHAP and G-CSF is a superior blood stem
cell mobilizing regimen compared to cyclophosphamide 1.5 g m(-2) and G-CSF for pretreated lymphoma patients: a matched pairs analysis of 78 patients. Br J Cancer
2000;82(2):278-82.
136. Lee JL, Kim S, Kim SW, et al. ESHAP plus G-CSF as an effective peripheral
blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma:
comparison with high-dose cyclophosphamide plus G-CSF. Bone Marrow Transplant
2005;35(5):449-54.
137. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8
radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell nonHodgkin's lymphoma. J Clin Oncol 1999;17(12):3793-803.
138. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy
for patients with relapsed or refractory low-grade, follicular, or transformed B-cell nonHodgkin's lymphoma. J Clin Oncol 2002;20(10):2453-63.
139. Watanabe T, Terui S, Itoh K, et al. Phase I study of radioimmunotherapy with an
anti-CD20 murine radioimmunoconjugate ((90)Y-ibritumomab tiuxetan) in relapsed or
refractory indolent B-cell lymphoma. Cancer Sci 2005;96(12):903-10.
140. Jacobs SA, Vidnovic N, Joyce J, McCook B, Torok F, Avril N. Full-dose 90Y
ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy.
Clin Cancer Res 2005;11(19 Pt 2):7146s-50s.
141. Wiseman GA, Gordon LI, Multani PS, et al. Ibritumomab tiuxetan
radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and
mild thrombocytopenia: a phase II multicenter trial. Blood 2002;99(12):4336-42.
142. Press OW, Unger JM, Braziel RM, et al. Phase II trial of CHOP chemotherapy
followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular
non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol
S9911. J Clin Oncol 2006;24(25):4143-9.
143. Kaminski MS, Radford JA, Gregory SA, et al. Re-treatment with I-131
tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to
I-131 tositumomab. J Clin Oncol 2005;23(31):7985-93.
144. Chen SC, Lin MC, Chang JW, Wang SW, Lee CH, Tsao TC. Phase II study of
regimen of gemcitabine and cisplatin in advanced non-small cell lung cancer. Jpn J Clin
Oncol 2000;30(11):494-8.
145. Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus
cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-smallcell lung cancer. J Clin Oncol 2000;18(1):122-30.
146. Crino L, Scagliotti G, Marangolo M, et al. Cisplatin-gemcitabine combination in
advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 1997;15(1):297-303.
147. Castellano D, Lianes P, Paz-Ares L, et al. A phase II study of a novel gemcitabine
plus cisplatin regimen administered every three weeks for advanced non-small-cell lung
cancer. Ann Oncol 1998;9(4):457-9.
148. Cardenal F, Lopez-Cabrerizo MP, Anton A, et al. Randomized phase III study of
gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or
metastatic non-small-cell lung cancer. J Clin Oncol 1999;17(1):12-8.
149. Van Zandwijk N, Smit EF, Kramer GW, et al. Gemcitabine and cisplatin as
induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung
cancer: a phase II study of the European Organization for Research and Treatment of
Cancer Lung Cancer Cooperative Group (EORTC 08955). J Clin Oncol
2000;18(14):2658-64.
150. Ricci S, Antonuzzo A, Galli L, et al. A randomized study comparing two different
schedules of administration of cisplatin in combination with gemcitabine in advanced
nonsmall cell lung carcinoma. Cancer 2000;89(8):1714-9.
151. Alberola V, Camps C, Provencio M, et al. Cisplatin plus gemcitabine versus a
cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell
lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol
2003;21(17):3207-13.
152. Zatloukal P, Petruzelka L, Zemanova M, et al. Gemcitabine plus cisplatin vs.
gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III
randomized trial. Lung Cancer 2003;41(3):321-31.
153. Cappuzzo F, Selvaggi G, Gregorc V, et al. Gemcitabine and cisplatin as induction
chemotherapy for patients with unresectable Stage IIIA-bulky N2 and Stage IIIB
nonsmall cell lung carcinoma: an Italian Lung Cancer Project Observational Study.
Cancer 2003;98(1):128-34.
154. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial
comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin
Oncol 2002;20(21):4285-91.
155. Vokes EE, Herndon JE, 2nd, Crawford J, et al. Randomized phase II study of
cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy
followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer:
cancer and leukemia group B study 9431. J Clin Oncol 2002;20(20):4191-8.
156. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with
etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med
2002;346(2):85-91.
157. Santo A, Pedersini R, Pasini F, et al. A phase II study of induction chemotherapy
with gemcitabine (G) and cisplatin (P) in locally advanced non-small cell lung cancer:
interim analysis. Lung Cancer 2001;34 Suppl 4:S15-20.
158. Novello S, Bruzzi P, Barone C, et al. Phase III study in stage IV non-small-cell
lung cancer patients treated with two courses of cisplatin/gemcitabine followed by a
randomization to three additional courses of the same combination or gemcitabine alone.
Ann Oncol 2007;18(5):903-8.
159. Langer C, Li S, Schiller J, Tester W, Rapoport BL, Johnson DH. Randomized
phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern
Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients:
ECOG 1599. J Clin Oncol 2007;25(4):418-23.
160. Kim JH, Kim SY, Jung KH, et al. Randomized phase II study of gemcitabine plus
cisplatin versus etoposide plus cisplatin for the treatment of locally advanced or
metastatic non-small cell lung cancer: Korean Cancer Study Group experience. Lung
Cancer 2006;52(1):75-81.
161. Rinaldi M, Crino L, Scagliotti GV, et al. A three-week schedule of gemcitabinecisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels:
a phase II randomized trial. Ann Oncol 2000;11(10):1295-300.
162. Wachters FM, Van Putten JW, Kramer H, et al. First-line gemcitabine with
cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial. Br J
Cancer 2003;89(7):1192-9.
163. Martoni A, Marino A, Sperandi F, et al. Multicentre randomised phase III study
comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine
or gemcitabine in advanced non-small cell lung cancer. Eur J Cancer 2005;41(1):81-92.
164. Mazzanti P, Massacesi C, Rocchi MB, et al. Randomized, multicenter, phase II
study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with
advanced non-small cell lung cancer. Lung Cancer 2003;41(1):81-9.
165. Gebbia V, Galetta D, Caruso M, et al. Gemcitabine and cisplatin versus
vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and
cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in
stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of
the Gruppo Oncologico Italia Meridionale. Lung Cancer 2003;39(2):179-89.
166. Migliorino MR, De Marinis F, Nelli F, et al. A 3-week schedule of gemcitabine
plus cisplatin as induction chemotherapy for Stage III non-small cell lung cancer. Lung
Cancer 2002;35(3):319-27.
167. Jassem J, Krzakowski M, Roszkowski K, et al. A phase II study of gemcitabine
plus cisplatin in patients with advanced non-small cell lung cancer: clinical outcomes and
quality of life. Lung Cancer 2002;35(1):73-9.
168. Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus
irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin
plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study
in Japan. Ann Oncol 2007;18(2):317-23.
169. Brodowicz T, Krzakowski M, Zwitter M, et al. Cisplatin and gemcitabine firstline chemotherapy followed by maintenance gemcitabine or best supportive care in
advanced non-small cell lung cancer: a phase III trial. Lung Cancer 2006;52(2):155-63.
170. Crino L, Scagliotti GV, Ricci S, et al. Gemcitabine and cisplatin versus
mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A
randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol
1999;17(11):3522-30.
171. Anton A, Diaz-Fernandez N, Gonzalez Larriba JL, et al. Phase II trial assessing
the combination of gemcitabine and cisplatin in advanced non-small cell lung cancer
(NSCLC). Lung Cancer 1998;22(2):139-48.
172. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy
regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346(2):92-8.
173. Georgoulias V, Ardavanis A, Tsiafaki X, et al. Vinorelbine plus cisplatin versus
docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III
randomized trial. J Clin Oncol 2005;23(13):2937-45.
174. Aravantinos G, Fountzilas G, Kosmidis P, et al. Paclitaxel plus carboplatin versus
paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced
ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group
(HeCOG) study. Ann Oncol 2005;16(7):1116-22.
175. Tredan O, Geay JF, Touzet S, et al. Carboplatin/cyclophosphamide or
carboplatin/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two
consecutive trials from the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers
Ovariens. Ann Oncol 2007;18(2):256-62.
176. Bell J, Brady MF, Young RC, et al. Randomized phase III trial of three versus six
cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma:
a Gynecologic Oncology Group study. Gynecol Oncol 2006;102(3):432-9.
177. Greimel ER, Bjelic-Radisic V, Pfisterer J, Hilpert F, Daghofer F, du Bois A.
Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian
Cancer Study Group comparing quality of life in patients with ovarian cancer treated with
cisplatin/paclitaxel versus carboplatin/paclitaxel. J Clin Oncol 2006;24(4):579-86.
178. Gonzalez-Martin AJ, Calvo E, Bover I, et al. Randomized phase II trial of
carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced
ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario)
study. Ann Oncol 2005;16(5):749-55.
179. Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxelcarboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian
carcinoma. J Natl Cancer Inst 2004;96(22):1682-91.
180. Bolis G, Scarfone G, Polverino G, et al. Paclitaxel 175 or 225 mg per meters
squared with carboplatin in advanced ovarian cancer: a randomized trial. J Clin Oncol
2004;22(4):686-90.
181. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel
compared with cisplatin and paclitaxel in patients with optimally resected stage III
ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21(17):3194200.
182. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel
in ovarian cancer. N Engl J Med 2006;354(1):34-43.
183. Burris HA, 3rd, Moore MJ, Andersen J, et al. Improvements in survival and
clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas
cancer: a randomized trial. J Clin Oncol 1997;15(6):2403-13.
184. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with
gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the
National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol
2007;25(15):1960-6.
185. Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial of
gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic
cancer. J Clin Oncol 2006;24(24):3946-52.
186. Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with
oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic
cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol
2005;23(15):3509-16.
187. Moore MJ, Hamm J, Dancey J, et al. Comparison of gemcitabine versus the
matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic
adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of
Canada Clinical Trials Group. J Clin Oncol 2003;21(17):3296-302.
188. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB, 3rd. Phase
III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in
patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial
E2297. J Clin Oncol 2002;20(15):3270-5.
189. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs
observation in patients undergoing curative-intent resection of pancreatic cancer: a
randomized controlled trial. Jama 2007;297(3):267-77.
190. Oettle H, Richards D, Ramanathan RK, et al. A phase III trial of pemetrexed plus
gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic
cancer. Ann Oncol 2005;16(10):1639-45.
191. Dragovich T, Huberman M, Von Hoff DD, et al. Erlotinib plus gemcitabine in
patients with unresectable pancreatic cancer and other solid tumors: phase IB trial.
Cancer Chemother Pharmacol 2007;60(2):295-303.
192. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or
mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med
2004;351(15):1502-12.
193. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus
prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a
Canadian randomized trial with palliative end points. J Clin Oncol 1996;14(6):1756-64.
194. Berry W, Dakhil S, Modiano M, Gregurich M, Asmar L. Phase III study of
mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with
asymptomatic hormone refractory prostate cancer. J Urol 2002;168(6):2439-43.
195. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine
compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N
Engl J Med 2004;351(15):1513-20.
196. Schild SE, Bonner JA, Hillman S, et al. Results of a phase II study of high-dose
thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage smallcell lung cancer (NCCTG 95-20-53). J Clin Oncol 2007;25(21):3124-9.
197. Eckardt JR, von Pawel J, Papai Z, et al. Open-label, multicenter, randomized,
phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment
for chemotherapy-naive patients with extensive-disease small-cell lung cancer. J Clin
Oncol 2006;24(13):2044-51.
198. Chen GY, Jiang GL, Wang LJ, et al. Cisplatin/etoposide chemotherapy combined
with twice daily thoracic radiotherapy for limited small-cell lung cancer: a clinical phase
II trial. Int J Radiat Oncol Biol Phys 2005;61(1):70-5.
199. Takada M, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus
sequential thoracic radiotherapy in combination with cisplatin and etoposide for limitedstage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J
Clin Oncol 2002;20(14):3054-60.
200. Mennecier B, Jacoulet P, Dubiez A, et al. Concurrent cisplatin/etoposide
chemotherapy plus twice daily thoracic radiotherapy in limited stage small cell lung
cancer: a phase II study. Lung Cancer 2000;27(3):137-43.
201. Turrisi AT, 3rd, Kim K, Blum R, et al. Twice-daily compared with once-daily
thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin
and etoposide. N Engl J Med 1999;340(4):265-71.
202. Ihde DC, Mulshine JL, Kramer BS, et al. Prospective randomized comparison of
high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with
extensive-stage small-cell lung cancer. J Clin Oncol 1994;12(10):2022-34.
203. Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of
cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus
alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of
the Southeastern Cancer Study Group. J Clin Oncol 1992;10(2):282-91.
204. Hanna N, Bunn PA, Jr., Langer C, et al. Randomized phase III trial comparing
irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated
extensive-stage disease small-cell lung cancer. J Clin Oncol 2006;24(13):2038-43.
205. Pujol JL, Daures JP, Riviere A, et al. Etoposide plus cisplatin with or without the
combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive smallcell lung cancer: a French Federation of Cancer Institutes multicenter phase III
randomized study. J Natl Cancer Inst 2001;93(4):300-8.
206. Kudoh S, Fujiwara Y, Takada Y, et al. Phase II study of irinotecan combined with
cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung
Cancer Group. J Clin Oncol 1998;16(3):1068-74.
207. Jeong HC, Lee SY, Lee SY, et al. Phase II study of irinotecan plus cisplatin with
concurrent radiotherapy for the patients with limited-disease small-cell lung cancer. Lung
Cancer 2006;53(3):361-6.
208. Sohn JH, Moon YW, Lee CG, et al. Phase II trial of irinotecan and cisplatin with
early concurrent radiotherapy in limited-disease small-cell lung cancer. Cancer
2007;109(9):1845-950.